TG Therapeutics Q4 net loss $93.3M; UKONIQ revenue $2.3M; FDA partial hold on U2

TG THERAPEUTICS, INC.

2022-FY EPS reported -$2.63 revenue$6,689,000

Net loss Q4 2021 $93.3M ($88.2M Q4 2020); full year net loss $348.1M ($279.4M 2020).
Product revenue from UKONIQ net $2.3M in Q4, $6.5M for full year 2021.
Cash, equivalents & securities $350.3M at Dec 31, 2021; funds operations into 2023.
FDA partial clinical hold on U2 (ublituximab + umbralisib) studies in CLL/NHL; ODAC meeting expected March/April 2022.
FDA accepted BLA for ublituximab in RMS (PDUFA Sept 28, 2022); BLA/sNDA for U2 in CLL/SLL pending ODAC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.